EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database

Yusuke Okuma, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Nobuyuki Yamamoto, Tomoya Kawaguchi, Etsuo Miyaoka, Ichiro Yoshino und 1 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Yusuke Okuma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metro…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In advanced non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations, those with impaired performance status (PS) treated with EGFR-tyrosine kinase inhibitors (TKIs) have demonstrated comparable activities to good-PS patients. Due to the limited sample size and inclusion of older adult patients with good PS, these findings may not accurately depict the efficacy of EGFR-TKI in poor-PS patients. We investigated the benefit of EGFR-TKIs in this population and identified relevant prognostic factors. PATIENTS AND METHODS: This nationwide prospective registry study included 9872 patients with local or advanced NSCLC. Outcomes were compared between poor- and good-PS patients treated with EGFR-mutated lung cancer therapies. RESULTS: Of 9872 NSCLC patients, 1965 (19.9%) had EGFR mutations, with 1846 (93.9%) presenting common EGFR mutations. Poor PS (PS score ≥ 3) was noted in 171 patients (8.7%) and identified as an independent prognostic factor; those with poor PS had a significantly lower 1-year survival rate. The median overall survival (OS) for EGFR-TKI-treated good-PS patients was 31.5 (95% confidence interval, 29.6-33.4) months. Among poor-PS patients with EGFR mutations, 135 (78.9%) of whom were treated with EGFR-TKI had an OS of 15.5 (12.7-18.3) months, while those receiving only supportive care had an OS of 2.5 (1.4-3.6) months (P < .001). Hypoalbuminemia (< 3.5 g/dL), liver metastasis, and uncommon EGFR mutations were associated with poor prognosis. CONCLUSION: Poor PS at diagnosis was rare and associated with limited EGFR-TKI efficacy and a dismal prognosis. Liver metastasis and hypoalbuminemia may reduce EGFR-TKI efficacy in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsProtein Kinase InhibitorsMutationRegistriesHumansMaleFemaleAgedMiddle AgedJapanPrognosisProspective StudiesAged, 80 and overAdultSurvival RateNeoplasm MetastasisTyrosine Kinase InhibitorsEast Asian People

Stichwörter der Autor:innen

EGFRNon-small cell lung cancerPoor performance statusTyrosine kinase inhibitor

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan. Electronic address: yokuma@nc…
  • Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Palliative Medicine, Tohoku University School of Medicine, Miyagi, Japan.

Zitieren

APA

Okuma, Y., Shintani, Y., Sekine, I., Shukuya, T., Takayama, K., Inoue, A., Okamoto, I., Kiura, K., Yamamoto, N., Kawaguchi, T., Miyaoka, E., Yoshino, I., & Date, H. (2024). Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.01.005

Vancouver

Okuma Y, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, et al. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.01.005

BibTeX
@article{Okuma2024,
  author = {Okuma, Yusuke and Shintani, Yasushi and Sekine, Ikuo and Shukuya, Takehito and Takayama, Koichi and Inoue, Akira and Okamoto, Isamu and Kiura, Katsuyuki and Yamamoto, Nobuyuki and Kawaguchi, Tomoya and Miyaoka, Etsuo and Yoshino, Ichiro and Date, Hiroshi},
  title = {Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.01.005}
}
Kostenlos starten →